Populations and Risk Factors
- Women of reproductive age — most common between 20 and 50 years. Resolves or improves after menopause
- Cyclic hormonal stimulation: estrogen promotes proliferation. Progesterone promotes cystic change in the luteal phase
- Associated with caffeine intake (some evidence of symptom exacerbation)
- Family history of fibrocystic changes or benign breast disease
- Hormone therapy (exogenous estrogen/progestins) may perpetuate symptoms post-menopausally
Causes and Pathophysiology
- Hormonal sensitivity: Breast glandular and stromal tissue responds excessively to normal cyclical hormonal changes. Estrogen drives epithelial proliferation. Progesterone drives cystic dilation
- Cyst formation: Duct obstruction causes fluid accumulation. Simple cysts are fluid-filled, smooth-walled, and benign
- Fibrosis: Stromal proliferation produces fibrous tissue creating nodularity and firmness
- Adenosis: Proliferation of lobular units. Sclerosing adenosis is a common subtype
- Atypical hyperplasia: A subset involving cellular atypia carries modestly elevated breast cancer risk. The vast majority of fibrocystic changes involve no atypia and no increased cancer risk
Signs and Symptoms
- Cyclic breast pain (mastalgia): Dull aching or heaviness in the outer upper quadrant. Worsens in the luteal phase (days before menstruation). Improves post-menstrually
- Breast nodularity: Multiple lumpy areas, typically bilateral and symmetrical. More prominent premenstrually
- Palpable cysts: Discrete, mobile, smooth, round, and tender lumps
- Breast tenderness: Diffuse sensitivity to touch or pressure
- Red flags: Any lump that is unilateral, non-cyclical, hard, fixed, or painless does NOT match the fibrocystic pattern — refer for medical evaluation to rule out malignancy
CMTO Exam Relevance
- Key differential from breast cancer: Fibrocystic lumps are bilateral, mobile, smooth-bordered, cyclically tender. Cancer masses are typically unilateral, hard, irregular, non-tender, non-cyclical
- Any new, non-cyclical, unilateral, or persistently changing breast lump requires referral — outside MT scope to assess
- Massage over the pectoral region is not contraindicated. Direct breast tissue massage requires explicit informed consent and is not standard practice unless specifically indicated (e.g., post-mastectomy lymphedema protocols)
Massage Therapy Considerations
- No systemic contraindication: Fibrocystic changes do not preclude general body treatment
- Chest and pectoral region: Massage to pectorals, intercostals, and anterior chest wall is appropriate. Avoid direct pressure over painful or tender breast tissue unless specifically indicated and consented
- Prone positioning: May be uncomfortable when breast tenderness is significant — offer chest bolster or use side-lying. Ask the client about comfort
- Pre-menstrual phase: Symptoms are worst 1-2 weeks before menstruation. Lighter pressure and comfort-focused sessions during this time
- Lump documentation: If a client mentions a lump that does not match the bilateral, cyclical pattern, document and refer — do not assess further
- Informed consent: Required for any breast tissue work regardless of diagnosis. Document in the treatment plan
Key Takeaways
- Fibrocystic breast changes are benign, common, and caused by hormonal sensitivity — cyclic bilateral breast pain and nodularity are the hallmarks
- The key clinical skill is distinguishing fibrocystic changes from breast cancer: bilateral vs. unilateral, mobile vs. fixed, cyclical vs. stable, tender vs. non-tender
- Any atypical lump (unilateral, non-cyclical, hard, fixed) requires referral — not MT assessment
- Massage is not contraindicated. Prone positioning may be uncomfortable during high-symptom phases
- Explicit informed consent is required for any direct breast tissue work